Altar M. Munis

PhD, BSc (Hons)

Postdoctoral Research Scientist

Funded by the Wellcome Trust, I am working on the development and optimisation of lentiviral gene therapy for lung diseases. In particular, my current project focuses on the treatment of surfactant protein B deficiency, a fatal autosomal recessive genetic disorder, using Sendai virus F/HN pseudotyped vectors.

Prior to joining the Gene Medicine group, I undertook my doctoral studies in gene therapy and immunology at University College London investigating the properties of phylogenetically distinct vesiculovirus glycoproteins that may have advantages over the prototypical glycoprotein from VSV Indiana strain.

Recent publications

Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom’s first national lockdown
Journal article

Munis AM. et al, (2021), Scientific Reports, 11
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.
Journal article

Downes DJ. et al, (2021), Nat Genet, 53, 1606 - 1615
A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
Journal article

Munis AM. et al, (2021), Molecular Therapy - Methods and Clinical Development, 20, 237 - 246
Genome-wide Integration Site Detection Using Cas9 Enriched Amplification-free Long-range Sequencing
Journal article

HYDE S. et al, (2020), Nucleic Acids Research
A tool with many applications: vesicular stomatitis virus in research and medicine.
Journal article

Munis AM. et al, (2020), Expert Opin Biol Ther, 20, 1187 - 1201

More publications